Alzheimer's Disease Precision Medicine Companies

Overview

Overview

This category page covers biotechnology and pharmaceutical companies developing precision medicine approaches for Alzheimer's disease. Precision medicine in AD involves tailoring treatments based on individual patient characteristics including genetic profile (particularly APOE genotype), biomarker status (ATN framework: Amyloid, Tau, Neurodegeneration), disease stage, and other personalized factors.

The main precision medicine approaches being developed include:

• APOE-targeted therapies - Gene therapy and small molecules targeting APOE4 carriers
• Biomarker-stratified trials - Enriching clinical trials based on amyloid, tau, and neurodegeneration biomarkers
• Genetic subtyping - Stratifying patients by genetic risk factors beyond APOE
• Personalized intervention timing - Matching treatment to disease stage for maximum efficacy

Key Companies

Lexeo Therapeutics

| Attribute | Value |
|-----------|-------|
| Focus | APOE-targeted gene therapy |
| Lead Candidate | LX1001 |
| Indication | APOE4 homozygous Alzheimer's disease |
| Stage | Phase 1/2 (LEAD trial) |
| Mechanism | Deliver APOE2 (protective allele) via AAV intrathecal delivery |
| Designations | FDA Fast Track |

Lexeo Therapeutics is developing the first gene therapy approach specifically for APOE4 homozygous patients - approximately 2-3% of AD cases but with ~12x increased risk compared to APOE3 carriers. The company delivers a functional APOE2 gene to neurons via intrathecal administration, potentially reducing amyloid deposition and improving tau pathology in this high-risk population. Lexeo has a strategic partnership with Eli Lilly (2023) and completed a Series C financing of $100+ million in 2024.

Additional programs include:

• LX1021: APOE Christchurch mutation carriers (preclinical)
• LX1020: APOE2+/E4- patients (preclinical)

Denali Therapeutics

| Attribute | Value |
|-----------|-------|
| Focus | Biomarker-stratified therapy (ATN framework) |
| Lead Candidates | DNL151 (LRRK2), DNL919 (TREM2), DNL310 |
| Indications | Alzheimer's disease, Parkinson's disease |
| Stage | Phase 1-3 |
| Platform | Brain Transport Vehicle (TVB) for BBB penetration |

Denali Therapeutics employs a precision medicine approach through biomarker-driven patient selection and their proprietary Brain Transport Vehicle technology. Their Alzheimer's pipeline focuses on TREM2 agonism (DNL919/ARCAM-1) which is being developed for patients with specific TREM2 variants. The company uses the ATN (Amyloid, Tau, Neurodegeneration) biomarker framework to stratify patients and match them with appropriate therapies. Denali has a $1.1B partnership with Biogen for their LRRK2 program and a partnership with Takeda for their MPS II program.

[@denali_corp][@biomarker_atn]

Cognivue

| Attribute | Value |
|-----------|-------|
| Focus | Personalized cognitive assessment |
| Product | Cognivue FDA-cleared self-administered device |
| Indication | Primary care cognitive screening |
| Stage | Commercial (FDA-cleared) |
| Mechanism | Objective cognitive assessment enabling early identification and personalized treatment planning |

Cognivue provides an FDA-cleared self-administered cognitive assessment device designed for primary care settings. This precision medicine tool enables quick cognitive screening to identify patients who need further evaluation, enabling earlier and more personalized intervention. The device provides objective measurements that can be used to track cognitive changes over time and guide treatment decisions.

[@cognivue_corp]

BrainStorm Cell Therapeutics

| Attribute | Value |
|-----------|-------|
| Focus | Personalized cell therapy |
| Product | NurOwn (autologous MSC-NTF cells) |
| Indications | Alzheimer's disease, ALS, MS |
| Stage | Phase 2 |
| Mechanism | Patient-derived mesenchymal stem cells secreting neurotrophic factors |

BrainStorm Cell Therapeutics is developing NurOwn, a personalized cell therapy approach that uses the patient's own (autologous) mesenchymal stem cells. These cells are engineered to secrete neurotrophic factors (MSC-NTF cells) that support neuronal survival and function. The personalized nature of the therapy - using the patient's own cells - represents a precision medicine approach tailored to individual patients. The therapy has completed Phase 2 trials for Alzheimer's disease.

[@brainstorm_corp]

Precision Medicine Framework

Biomarker Stratification (ATN)

The ATN framework is central to AD precision medicine:

| Biomarker Category | Markers | Purpose |
|-------------------|---------|---------|
| A (Amyloid) | PET, CSF Aβ42/40 | Confirm amyloid pathology |
| T (Tau) | PET, CSF p-tau | Assess tau pathology burden |
| N (Neurodegeneration) | MRI, FDG-PET, CSF total-tau | Measure neuronal damage |

APOE Genotype-Guided Approaches

| APOE Status | AD Risk | Precision Approach |
|-------------|---------|-------------------|
| APOE4/E4 | ~12x increased | Gene therapy (Lexeo), aggressive prevention |
| APOE4/E3 | ~3-4x increased | Targeted immunotherapy, earlier intervention |
| APOE3/E3 | Baseline | Standard approaches |
| APOE2/E3 | Protective | Potential for prevention studies |

Development Landscape

The precision medicine approach in AD is evolving rapidly, with multiple companies developing:

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [APOE Gene](/genes/apoe)
• [Biomarkers in AD - ATN Framework](/biomarkers/atn-biomarkers)
• [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)
• [Cell Therapy for AD](/companies/ad-cell-therapy-companies)

External Links

• [Lexeo Therapeutics](https://www.lexeotx.com)
• [Denali Therapeutics](https://www.denalitherapeutics.com)
• [Cognivue](https://www.cognivue.com)
• [BrainStorm Cell Therapeutics](https://www.brainstorm-cell.com)
• [ClinicalTrials.gov - AD Precision Medicine](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=precision+medicine)

References